DARA BioSciences to Present at 25th Annual ROTH Conference

DARA BioSciences to Present at 25th Annual ROTH Conference 
RALEIGH, NC  -- (Marketwire) -- 03/18/13 --   DARA BioSciences, Inc.
(NASDAQ: DARA), a specialty pharmaceutical company focused on
oncology and oncology supportive care products, announced today that
David J. Drutz, M.D., Chief Executive Officer and Chief Medical
Officer, will be presenting a corporate overview at the 25th Annual
ROTH Conference on Wednesday, March 20, 2013 at 11:00 a.m. Pacific
Time. The conference is being held at The Ritz-Carlton, Laguna Niguel
in Dana Point, California.  
A live audio broadcast will be available under the "Investors"
section of DARA's website at www.darabio.com. The live audio
broadcast will be available through June 15, 2013. 
About DARA BioSciences, Inc.  
DARA is a specialty pharmaceutical company focused on the development
and commercialization of oncology treatment and supportive care
products. DARA has comprehensive commercial coverage across the
national oncology market through a series of agreements with a number
of specialty pharmacy providers, leading group purchasing
organizations (GPOs), retail partners, reimbursement experts, and an
industry-leading third-party logistics provider. As part of an
integrated national network with annual sales of over $1 billion in
cancer therapeutics, DARA has significant commercial scale and
capabilities. Its distribution network consists of more than 45,000
retail pharmacies, mail order pharmacies, and long-term care
facilities. This provides DARA with established reimbursement and
logistics expertise, as well as partnering opportunities with more
than 300 sales and marketing personnel uniquely focused on oncology
and oncology support products. This comprehensive network of partners
is rare if not unique among companies in the oncology supportive care
area and provides DARA a strong foundation for product introductions
into this underserved market.  
DARA increased its focus in oncology through its January 2012
acquisition of Oncogenerix, Inc., which holds the exclusive U.S.
marketing rights to Soltamox®, a novel oral liquid formulation of
tamoxifen citrate, which is widely used in the treatment and
prevention of breast cancer. Soltamox is the only FDA-approved oral
liquid version of tamoxifen citrate and fulfills a vital clinical
need for patients who cannot tolerate existing solid tablet
formulations of this drug. DARA launched Soltamox in October 2012 to
coincide with National Breast Cancer Awareness Month. DARA has
exclusive U.S. rights to Soltamox through a license from Rosemont
Pharmaceuticals, Ltd. Additionally, in June 2012, DARA launched its
first product, Bionect®, a topical treatment for skin irritation and
burns associated with radiation therapy. DARA has rights to market
Bionect in the US oncology/radiology markets under license from
Innocutis. DARA also has exclusive U.S. commercial rights to
Gelclair®, an FDA-cleared product for the treatment of oral
mucositis, which DARA plans to launch in April, 2013.  
DARA is also developing a cancer-support therapeutic compound,
KRN5500, for the treatment of chronic chemotherapy-induced peripheral
neuropathy (CCIPN) in patients with cancer. This product is an
excellent fit with DARA's strategic oncology focus, has successfully
completed a Phase 2a clinical trial, and has been designated a Fast
Track Drug by the FDA. DARA has created an improved, commercializable
formulation of this drug and is in active partnering discussions
regarding further clinical development. DARA has also submitted an
Orphan Drug Application to the FDA for the use of this drug in CCIPN. 
In addition to its oncology products, DARA's pipeline includes DB959,
a novel, non-TZD dual delta/gamma PPAR agonist for the treatment of
type 2 diabetes and dyslipidemia. DARA has completed Phase 1 testing
of DB959 and is presently pursuing opportunities to out-license this
product. For more information please visit our web site at
www.darabio.com.  
Safe Harbor Statement 
All statements in this news release that are not historical are
forward-looking statements within the meaning of the Securities
Exchange Act of 1934, as amended. Such forward-looking statements are
subject to factors that could cause actual results to differ
materially for DARA from those projected. Those factors include risks
and uncertainties relating to DARA's ability to timely commercialize
and generate revenues or profits from Bionect®, Soltamox®, Gelclair®
or other products given that DARA only recently hired its initial
sales force and DARA's lack of history as a revenue-generating
company, FDA and other regulatory risks relating to DARA's ability to
market Bionect, Soltamox, Gelclair or other products in the U.S. or
elsewhere, DARA's ability to develop and bring new products to market
as anticipated, DARA's current cash position and its need to raise
additional capital in order to be able to continue to fund its
operations, the current regulatory environment in which DARA develops
and sells its products, the market acceptance of those products,
dependence on partners, successful performance under collaborative
and other commercial agreements, competition, the strength of DARA's
intellectual property and the intellectual property of others, the
potential delisting of DARA's common stock from the NASDAQ Capital
Market, risks and uncertainties relating to DARA's ability to
successfully integrate Oncogenerix and other risk factors identified
in the documents DARA has filed, or will file, with the Securities
and Exchange Commission ("SEC"). Copies of DARA's filings with the
SEC may be obtained from the SEC Internet site at http://www.sec.gov.
DARA expressly disclaims any obligation or undertaking to release
publicly any updates or revisions to any forward-looking statements
contained herein to reflect any change in DARA's expectations with
regard thereto or any change in events, conditions, or circumstances
on which any such statements are based. DARA BioSciences and the DARA
logo are trademarks of DARA BioSciences, Inc.  
CONTACT: 
Jenene Thomas
Investor Relations + Corporate Communications Advisor
+1-908-938-1475
jthomas@darabio.com